Inhibition of OS via the Nrf2, SIRT1, and TXN signaling pathways has shown promising results in animal models, demonstrating the potential of antioxidant therapy in preventing and controlling BPD. The gene discussed is SIRT1; the disease is bronchopulmonary dysplasia.